Welcome to our dedicated page for Syros Pharmaceuticals news (Ticker: SYRS), a resource for investors and traders seeking the latest updates and insights on Syros Pharmaceuticals stock.
Syros Pharmaceuticals, Inc. (SYRS) is a pioneering life sciences company dedicated to transforming the treatment landscape for various diseases by strategically mapping gene regulatory circuits and modulating the factors that control gene expression. Syros stands out in the pharmaceutical industry for its groundbreaking gene control research and drug discovery capabilities, which integrate disease biology and genomic data in ways that are not commonly seen in traditional pharmaceutical R&D.
At the heart of Syros' innovative approach is a proprietary platform composed of advanced assay technologies, sophisticated bioinformatics, and deep biological insights. This platform, developed by Syros' seasoned senior leadership team, is designed to decode the complexities of gene regulation and uncover new therapeutic avenues.
While the scientific approach of Syros has broad applications across multiple therapeutic areas, the company has achieved notable success in oncology. Syros is working to address significant unmet medical needs, particularly in the treatment of hematologic malignancies, by developing new standards of care for frontline patient treatment.
Syros Pharmaceuticals is currently involved in several promising projects and partnerships aimed at advancing its clinical pipeline and expanding its impact on patient care. The company’s recent achievements and ongoing projects underscore its commitment to harnessing gene control research to develop innovative therapies.
Financially, Syros is strategically positioned to continue its research and development efforts, supported by robust funding and a clear vision for the future of precision medicine. With a focus on oncology, Syros continues to push the boundaries of what is possible in medical science, aiming to deliver groundbreaking treatments that can significantly improve patient outcomes.
Syros Pharmaceuticals (NASDAQ:SYRS) announced that CEO Nancy Simonian will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14 at 10:00 a.m. ET in New York. The company's innovations focus on controlling gene expression with a clinical-stage pipeline that includes treatments for higher-risk myelodysplastic syndrome, acute myeloid leukemia, and acute promyelocytic leukemia. A live webcast will be available on their website, with an archived replay accessible for 30 days post-event.
Syros Pharmaceuticals (NASDAQ: SYRS) has announced the grant of restricted stock unit (RSU) awards totaling 8,200 shares to two new employees, effective August 30, 2022. These awards serve as material inducements for employment under Nasdaq Listing Rule 5635(c)(4). The vesting schedule includes one award vesting quarterly starting from March 31, 2023, and an additional award beginning August 31, 2023, contingent upon continued service with the company. Syros is focused on developing gene expression medicines targeting various cancers.
Syros Pharmaceuticals (SYRS) announced promising preliminary pharmacokinetic data for SY-2101, an oral form of arsenic trioxide, showing comparable exposure to IV ATO. The company plans to initiate a Phase 3 trial for SY-2101 in APL by late 2023. Following a merger with TYME Technologies, expected to close in the second half of 2022, Syros anticipates raising ~$190 million, extending its cash runway into 2025. Financial results showed a revenue of $6.3 million for Q2 2022, up from $5.2 million in 2021, but with a net loss of $34.5 million. Cash reserves were $86.3 million as of June 30, 2022.
Syros Pharmaceuticals (NASDAQ: SYRS) announced a grant of 31,000 restricted stock units (RSUs) to a newly hired employee as an inducement for employment. This grant aligns with Nasdaq rule 5635(c)(4) and was awarded on July 29, 2022. The RSUs vest in four increments, with the first quarter vesting on March 31, 2023, and subsequent quarters annually, contingent on continued employment. Syros is focused on developing gene expression control medicines, with a pipeline that includes treatments for acute myeloid leukemia and solid tumors.
Syros Pharmaceuticals (NASDAQ:SYRS) announced that the European Medicines Agency (EMA) has issued a positive opinion for orphan drug designation for tamibarotene, aimed at treating myelodysplastic syndrome (MDS). This designation follows the FDA's granting of the same status in February 2022. Tamibarotene is currently being evaluated in the SELECT-MDS-1 Phase 3 trial alongside azacitidine for higher-risk MDS patients. Results from this trial are due in late 2023 or early 2024, with a potential new drug application filing anticipated next year.
Syros Pharmaceuticals (NASDAQ:SYRS) announced a live conference call and webcast on August 9, 2022, at 8:30 a.m. ET to discuss its second quarter 2022 financial results and provide a corporate update. Investors can access the call by dialing (833) 636-1323 domestically or (412) 902-4279 internationally, or via its website. Syros is focused on developing innovative medicines that control gene expression, with a robust pipeline including tamibarotene for myelodysplastic syndrome and acute myeloid leukemia, among other candidates.
Syros Pharmaceuticals announced a merger agreement to acquire TYME Technologies, gaining approximately
Syros Pharmaceuticals (NASDAQ: SYRS) announced the grant of restricted stock units (RSUs) for 48,400 shares to two new employees as an employment inducement per Nasdaq Listing Rule 5635(c)(4). The RSUs vest annually over four years, contingent on continued service. Syros is focused on gene expression control, advancing a clinical pipeline that includes tamibarotene for myelodysplastic syndrome, SY-2101 for acute promyelocytic leukemia, and SY-5609 for select solid tumors.
Syros Pharmaceuticals (NASDAQ:SYRS) announced that CEO Nancy Simonian will participate in a fireside chat at the JMP Securities Life Sciences Conference on June 15 at 9:30 a.m. ET, held at The Lotte New York Palace, NY. Attendees can join via a live webcast on Syros's website, with an archived replay available for 30 days. Syros focuses on developing medicines that control gene expression for diseases like myelodysplastic syndrome and leukemia, with a clinical pipeline that includes innovative treatments such as tamibarotene and SY-2101.
Syros Pharmaceuticals (NASDAQ: SYRS) has granted an aggregate of 77,850 restricted stock units (RSUs) to four new employees, effective May 31, 2022. These RSUs serve as material inducements in accordance with Nasdaq Listing Rule 5635(c)(4) and will vest over four years, subject to the employees’ continued service. Syros aims to leverage its gene control technology in advancing treatments for certain cancers, with a clinical pipeline that includes innovative therapies like tamibarotene and SY-5609.
FAQ
What is the current stock price of Syros Pharmaceuticals (SYRS)?
What is the market cap of Syros Pharmaceuticals (SYRS)?
What does Syros Pharmaceuticals specialize in?
What is unique about Syros Pharmaceuticals' approach?
In which therapeutic areas has Syros Pharmaceuticals shown success?
What recent achievements has Syros Pharmaceuticals made?
What is the financial condition of Syros Pharmaceuticals?
What is the proprietary platform of Syros Pharmaceuticals?
How does Syros Pharmaceuticals impact patient treatment?
Where is Syros Pharmaceuticals making its mark in the pharmaceutical industry?
Who are the key contributors to Syros Pharmaceuticals' proprietary platform?
What is the mission of Syros Pharmaceuticals?
